NL-OMON42468已完成不适用
Third population-based immune surveillance study for the evaluation of the National Immunisation Programme in the Netherlands: the PIENTER3 study - PIENTER3
RIVM0 个研究点目标入组 8,400 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 8,400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 2 至 99（—）
入选标准
- •* Subject is part of the study sample, aged 0 to 89 years old and has received a personal invitation for the PIENTER3 study.
- •* Subject has given written Informed Consent (IC) before the start of the study visit.
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Third population-based immune surveillance study used for the evaluation of immunity against SARS-CoV-2COVID-19SARS-CoV-210047438NL-OMON52416RIVM11,229
招募中
不适用
Immunity against SARS-CoV-2 in Dutch populatio<p>COVID-19, SARS-CoV-2</p>NL-OMON21435ational Institute for Public Health and the Environment (RIVM)14,000
尚未招募
不适用
PIENTER-onderzoekThe age-specific seroprevalence (immunity) for diseases included in the NIP of the Dutch general populationNL-OMON24544ational Institute for Public Health and the Environment (RIVM)8,400
已完成
不适用
A prospective observational study of immune-checkpoint inhibitor (Nivolumab) treatment in patients with non-small cell lung canceron-small cell lung cancerJPRN-UMIN000021600Kitasato University School of Medicine52
进行中（未招募）
1 期
Monitoring response on COVID-19 vaccination in children with cancerChildren with cancer, receiving COVID-19 vaccinationEUCTR2021-003388-90-NLPrincess Máxima Center for Pediatric Oncology130